Clinical trialPhase 2Completed
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
A Phase II Study of MLN0128 (TAK-228) in Rapalog-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 28 April 2017
- Ended
- 21 December 2022
- Enrollment
- 13 participants
- Sites
- 405
- Primary outcomes
- Overall Response Rate
- Sponsor type
- NIH
- Results posted
- 5 April 2022
- Last update
- 17 October 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 17 October 2023
- ORR
- Overall Response RateArm A (MLN0128): 0 (0 to 0.26), n = 12Values: proportion of participants, 95% Confidence IntervalTime frame: Assessed every 3 months for the first 2 years, every 6 months for the 3rd year, then annually up to 5 yearsNo analysis posted for this outcome (outcome 1)
- Participants
- Arm A (MLN0128): 13 started, 0 completed
- Serious adverse events
- Arm A (MLN0128): 7 of 13Participants with at least one serious adverse event, of those at risk, as posted
- Reported in
- A phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine tumors (PNET): ECOG… DOI 10.1007/s10637-022-01311-w↗ Linked as this trial’s results paper. The numbers above are the registry’s, not the paper’s.
3 secondary outcomes, the first 2 shown
- PFS · Progression-free Survival (PFS)
- Arm A (MLN0128) 5.19 (3.84 to 9.3), n=12 [median months, 95% Confidence Interval]
- DCR · Disease Control Rate
- Arm A (MLN0128) 0.67 (0.35 to 0.90), n=12 [proportion of participants, 95% Confidence Interval]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or shrink tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description public domain (ClinicalTrials.gov)
PRIMARY OBJECTIVE: I. To evaluate overall response rate associated with sapanisertib (MLN0128 \[TAK-228\]) in patients with advanced pancreatic neuroendocrine tumors (PNETs). SECONDARY ENDPOINTS: I. To evaluate progression-free survival (PFS) associated with MLN0128 (TAK-228) in patients with advanced pancreatic neuroendocrine tumors (PNETs). II. To measure the safety and tolerability of MLN0128 (TAK-228) in patients with advanced PNETs. III. To evaluate disease control rate associated with MLN0128 (TAK-228) in patients with advanced PNETs. IV. To measure duration of response rate associated with MLN0128 (TAK-228) in patients with advanced PNETs. OUTLINE: Patients receive sapanisertib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 1 year, and then yearly for 2 years.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Response Rate [Assessed every 3 months for the first 2 years, every 6 months for the 3rd year, then annually up to 5 years]. Number, proportion of participants (95% Confidence Interval). Arm A (MLN0128) (n=12): 0 (0 to 0.26).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Progression-free Survival (PFS) [Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years]. Median, months (95% Confidence Interval). Arm A (MLN0128) (n=12): 5.19 (3.84 to 9.3).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Disease Control Rate [Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years]. Number, proportion of participants (95% Confidence Interval). Arm A (MLN0128) (n=12): 0.67 (0.35 to 0.90).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Duration of Response [Assessed every 3 months for 2 years, every 6 months for the 3rd year, then annually up to 5 years].
Papers 1
- Registry-listed results paperA phase II study of sapanisertib (TAK-228) a mTORC1/2 inhibitor in rapalog-resistant advanced pancreatic neuroendocrine… DOI 10.1007/s10637-022-01311-w↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.